Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This journal is © the Partner Organisations 2022

Supporting Information

A New Type of Heterogeneous Catalysis Strategy for Organic Reaction: Highly

Stable MOFs with Exposed Carboxyl Groups Catalyzed Ugi-3CR

Jinni Liu^{a†}, Yongshuang Li^{a†}, Na Liu^a, Nianyu Huang^b, Long Wang^{a,c}* and Dongsheng Li^{a,c}*

^a Key laboratory of inorganic nonmetallic crystalline and energy conversion materials, College of

Materials and Chemical Engineering, China Three Gorges University, Yichang, Hubei 443002, China.

^b Hubei Key Laboratory of Natural Products Research and Development, College of Biological and

Pharmaceutical Science, China Three Gorges University, Yichang, Hubei 443002, China.

^c Hubei Three Gorges Laboratory, Yichang, Hubei 443007, China.

[†]*These authors contributed equally to this work.*

Email: wanglongchem@ctgu.edu.cn; lidongsheng1@126.com, Tel./fax: +86 0717 6397505

Table of contents

1. Experimental section
1.1 General Information S3
1.2 Preparation of Cu-COOH@MOF-6 S3
1.3 Preparation of Cu-MOF-4 S3
1.4 Typical Procedure for the Synthesis of 4
1.5 Typical Procedure for the Synthesis of 5
2. X-ray Crystallography S4
3. XRD of Cu-COOH@MOF-6 S5
4. Characterization data of the products 4 and 5
5. Copies of ¹ H and ¹³ C NMR spectra of compounds 4 and 5

1. Experimental section

1.1 General Information

Reactions were monitored by analytical thin-layer chromatography (TLC) on Silica gel plates (GF254). The TLC plates were isualized by shortwave (254 nm) or longwave (365 nm) UV light. Column chromatography was carried out using silica gel (200-300 mesh) to purify the product. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded in CDCl₃ on Bruker AVANCE III 400 MHz spectrometers using TMS as the internal standard (CDCl₃ δ_H = 7.26 ppm, downfield from TMS, δ_C = 77.16 ppm). Chemical shifts are given in ppm downfield from tetramethylsilane (TMS) as an internal reference, and coupling constants (J-values) are in Hertz (Hz). ¹H NMR assignment abbreviations are the following; singlet (s), doublet (d), triplet (t), quartet (q), broad singlet (bs), doublet of doublets (dd), triplet of doublets (td), doublet of a triplets (dt) and multiplet (m). The high-resolution mass spectra (HRMS) were recorded in waters G2-Xs qtof mass spectrometer. Melting points were measured using a WRR point instrument and are uncorrected. All reagents and solvents were purchased from commercial sources and used without further purification. All the reaction was under air atmosphere.

1.2 Preparation of Cu-COOH@MOF-6

Cu (ClO₄)₂·6H₂O (29.64 mg, 0.08 mmol), Br₄-H₂pta (19.27 mg, 0.04 mmol), and 2,2'-bpy (3.12 mg, 0.02 mmol), HNO₃ (1 M, 0.8 mL) were dissolved in deionized water (10 mL). The solution was stirred at room temperature for 10 minutes, and then the mixture was transferred into a 25 mL teflonlined stainless steel vessel and heated at 120 °C for 3 days under autogenous pressure, followed by cooling slowly to room temperature. Blue blocked crystals were collected by filtration after washing with deionized water and allowed to dry in air. Blue blocked crystals were obtained by filtration with yields up to 93%.

 Br_4 - $H_2pta = tetrabromobenzoic acid, 2,2'-bpy = 2,2'-dipyridyl.$

1.3 Preparation of Cu-MOF-4

Cu-MOF-4 was synthesized in a similar way to that of Cu-COOH@MOF-6, except that KOH (0.1 M, 0.8 mL) was used instead of HNO3 (1 M, 0.8 mL). Finally, blue blocked crystals were obtained by filtration with yields up to 91%.

1.4 Typical Procedure for the Synthesis of 4



A 50 mL round bottom flask was filled with aldehyde **1** (1.0 mmol, 1.0 equiv) and 3 mL methanol of the solvent. Then amine **2** (1.0 mmol, 1.0 equiv), isocyanide **3** (1.0

mmol, 1.0 equiv) and Cu-COOH@MOF-6 catalyst (0.1 mol %) were added and the reaction mixture was stirred for 12 h at atmospheric temperature until the reaction was completed (TLC). After completion, the crude product and catalyst were collected by filtration. The crude product was directly subjected to flash chromatography on silica gel column chromatography with petroleum ether/ethyl acetate to give pure product **4**.

1.5 Typical Procedure for the Synthesis of 5



Procedure for starting materials 1: Around bottom flask equipped with a stir bar was charged with the 2-nitrobenzaldehyde (30 mmol, 1.0 equiv) and NaN₃ (60 mmol, 2.0 equiv) in HMPA (2.5 equiv). The flask was not sealed and in contact with air. Under stirring constantly, the flask was then placed in an oil bath and heated to 60 °C for 24 h. After completion, the reaction solution was cooled to room temperature and poured into deionized water (0 °C) with uniform stirring and left to stand. Subsequently, gradual precipitation of a yellowish solid was observed. After all the solids were precipitated, o-azidobenzaldehyde was obtained by simple washing, filtration and drying.

Procedure for target compounds 5: In a round bottom flask, a mixture of oazidobenzaldehyde 1 (1 mmol, 1 equiv) was dissolved in 2 mL of MeOH solution and the amine 2 (1 mmol, 1 equiv), Cu-COOH@MOF-6 catalyst (0.1 mol %) were added sequentially and 1 mL of MeOH was added after 5 min of reaction. Subsequently, isonitrile 3 was added and stirred at room temperature for 12-24 h. The solvent was removed by distillation under reduced pressure after completion. The residue was purified by silica gel flash column chromatography eluting with the mixture of petroleum/ethyl acetate ether which eventually afforded the pure product 5.

2. X-ray Crystallography



Fig. S1 Crystal structure of Cu-COOH@MOF-6 and Cu-MOF-4

3. XRD of Cu-COOH@MOF-6



Fig. S2 Comparison of XRD patterns of Cu-COOH@MOF-6 before and after the reaction.

Diffraction data for the Cu-COOH@MOF-6 and Cu-MOF-4 were collected on a XtaLAB PRO MM003(Cu) using graphite monochromated Cu K α radiation (λ = 1.54184 Å) with the ϕ/ω scan technique. The crystal structures were solved by intrinsic phasing methods and refined by the full-matrix least-squares methods on F² using Olex2-1.5 and SHELXTL. The non-hydrogen atoms were refined anisotropically. The details of crystal data and structure refinement are given in Table S1. The selected bond lengths and bond angles of Cu-COOH@MOF-6 and Cu-MOF-4 are given in Table S1, respectively. CCDC numbers: 2132560 for Cu-COOH@MOF-6 and 2132613 for Cu-MOF-4. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Table S1. Crystal data and structure refinement parameters of Cu-COOH@MOF-6 andCu-MOF-4

Cu-MOFs	Cu-COOH@MOF-6	Cu-MOF-4
Empirical formula	$C_{26}H_{12}Br_8CuN_2O_9$	$C_{18}H_8Br_4CuN_2O_4$
Formula weight	1199.20	699.44
Temperature/K	100.00(10)	293(2)
Crystal system	monoclinic	triclinic
Space group	$P2_{1}/c$	P-1
a/Å	8.65370(10)	11.5369(2)
b/Å	32.2130(3)	12.8295(2)
c/Å	12.2035(2)	15.1063(3)
$\alpha/^{\circ}$	90	70.620(2)
β/°	109.870(2)	81.490(2)

$\gamma/^{\circ}$	90	88.3090(10)
Volume/Å ³	3199.34(8)	2085.55(7)
Z	4	4
pcalcg/cm ³	2.490	2.228
μ/mm^{-1}	13.165	10.713
F(000)	2252.0	1324.0
2 Θ range for data collection/°	5.486 to 130.174	7.306 to 133.184
Index ranges	$-10 \le h \le 9,$ $-37 \le k \le 34,$ $-14 \le l \le 14$	$-13 \le h \le 13,$ $-15 \le k \le 14,$ $-17 \le 1 \le 15$
Reflections collected	14898	21357
Independent reflections	5303 [Rint = 0.0255, Rsigma = 0.0273]	7344 [Rint = 0.0417, Rsigma = 0.0425]
Data/restraints/parameters	5303/0/425	7344/0/523
Goodness-of-fit on F ²	1.124	1.040
Final R indexes [I>= 2σ (I)]	R1 = 0.0237, w $R2 = 0.0547$	R1 = 0.0324, w $R2 = 0.0833$
Final R indexes [all data]	R1 = 0.0255, wR2 = 0.0555	R1 = 0.0357, w $R2 = 0.0855$
${}^{a}R = \Sigma I F_{0} - F_{C} I / \Sigma F_{0} ; {}^{b}wR_{2} =$	$\sum [w(F_0^2 - F_c^2)^2] / \sum [(F_0^2)^2]$	$l^{1/2}$

3. Characterization data of the products 4 and 5

2-(4-bromophenyl)-N-(tert-butyl)-2-((4-methoxyphenyl) amino) acetamide



White solid, 340 mg, 87% yield, mp 118-119 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.50 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 6.77 (d, J = 8.9 Hz, 2H), 6.61 – 6.56 (m, 3H), 4.49 (s, 1H), 4.17 (s, 1H), 3.74 (s, 3H), 1.31 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 169.89, 153.27, 140.51, 138.36,

132.29, 128.86, 122.28, 115.12, 114.78, 65.04, 55.65, 51.17, 28.51. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{19}H_{23}BrN_2O_2$ 391.1021; found 391.1017.

N-(tert-butyl)-2-((4-methoxyphenyl) amino)-2-phenylacetamide



White solid, 268 mg, 86% yield, mp 116-117 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.44 – 7.30 (m, 5H), 6.81 – 6.75 (m, 2H), 6.72 (s, 1H), 6.62 – 6.57 (m, 2H), 4.52 (s, 1H), 4.18 (s, 1H), 3.75 (s, 3H), 1.32 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 170.47, 153.12, 140.86, 139.34, 129.12, 128.37, 127.29, 115.02, 114.73, 65.80, 55.65, 51.02, 28.52. HRMS (ESI-TOF) m/z [M+H]⁺

calcd for $C_{18}H_{23}N_2O$ 313.1916; found 313.1956.

N-(tert-butyl)-2-(4-fluorophenyl)-2-(m-tolylamino) acetamide



White solid, 270 mg, 89% yield, mp 128-129 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.39 (dd, J = 8.6, 5.3 Hz, 2H), 7.10 – 7.04 (m, 3H), 6.64 (d, J = 7.5 Hz, 1H), 6.59 (s, 1H), 6.46 – 6.42 (m, 2H), 4.57 (d, J = 2.1 Hz, 1H), 4.32 (s, 1H), 2.27 (s, 3H), 1.32 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 170.14, 163.85, 161.39,

146.59, 139.19, 135.14, 135.11, 129.15, 129.05, 128.97, 120.20, 116.17, 115.96, 114.66, 111.06, 64.25, 51.17, 28.50, 21.52. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{19}H_{23}FN_2O$ 315.1873; found 315.1876.

N-(tert-butyl)-2-(4-methoxyphenyl)-2-(phenylamino) acetamide



White solid, 281 mg, 90% yield, mp 139-140 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.33 (d, *J* = 8.5 Hz, 2H), 7.18 (t, *J* = 7.8 Hz, 2H), 6.90 (d, *J* = 8.5 Hz, 2H), 6.79 (t, *J* = 7.3 Hz, 1H), 6.62 (d, *J* = 7.9 Hz, 2H), 6.52 (s, 1H), 4.54 (s, 1H), 4.44 (s, 1H), 3.80 (s, 3H), 1.31 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 170.49, 159.58, 146.82,

131.36, 129.20, 128.45, 118.93, 114.52, 113.84, 77.32, 77.00, 76.68, 64.20, 55.28, 51.08, 28.52. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{19}H_{24}N_2O_2$ 313.1916; found 313.1918.

N-(tert-butyl)-2-(2-chlorophenyl)-2-(m-tolylamino) acetamide



White solid, 274 mg, 83% yield, mp 139-140 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.47 – 7.40 (m, 2H), 7.25 – 7.23 (m, 2H), 7.02 (t, *J* = 7.7 Hz, 1H), 6.55 (d, *J* = 7.4 Hz, 1H), 6.41 (s, 1H), 6.35-6.33 (m, 2H), 5.18 (d, *J* = 4.3 Hz, 1H), 4.86 (d, *J* = 3.8 Hz, 1H), 2.24 (s, 3H), 1.32 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 169.21, 146.21, 139.02, 137.21, 133.17, 129.78, 129.28, 129.09, 128.49,

127.78, 119.40, 114.39, 110.51, 59.48, 51.51, 28.55, 21.53. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{19}H_{23}ClN_2O$ 331.1577; found 331.1575.

2-((3-bromophenyl) amino)-N-(tert-butyl)-2-(o-tolyl) acetamide



White solid, 318 mg, 85% yield, mp 142-143 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.33 – 7.31 (m, 1H), 7.24 – 7.22 (m, 3H), 7.03 (t, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 7.9 Hz, 1H), 6.78 (s, 1H), 6.54 (d, *J* = 10.0 Hz, 1H), 6.40 (s, 1H), 4.79 (d, *J* = 2.7 Hz, 1H), 4.42 (s, 1H), 2.38 (s, 3H), 1.34 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 170.00, 148.30, 137.02, 136.87, 131.33, 130.59, 128.51, 126.80, 123.20, 121.86,

116.45, 112.14, 61.35, 51.35, 28.55, 19.50. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{19}H_{23}BrN_2O$ 375.1072; found 375.1074.

2-((4-bromophenyl) amino)-N-(tert-butyl)-2-(4-methoxyphenyl) acetamide



White solid, 343 mg, 88% yield, mp 130-131 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.32 (d, J = 8.7 Hz, 2H), 7.00 (t, J = 8.0 Hz, 1H), 6.92-6.86 (m, 3H), 6.74 (t, J = 2.0 Hz, 1H), 6.51 (d, J = 8.2 Hz, 1H), 6.19 (s, 1H), 4.73 (d, J = 2.2 Hz, 1H), 4.53 (d, J = 2.6 Hz, 1H), 3.80 (s, 3H), 1.31 (s, 9H); ¹³C NMR (100 MHz,

CDCl₃) δ (ppm) 169.85, 159.73, 147.92, 130.80, 130.46, 128.36, 123.09, 121.51, 116.53, 114.63, 112.34, 63.30, 55.41, 51.33, 28.63. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₁₉H₂₃BrN₂O₂ 391.1021; found 391.1025.

N-(tert-butyl)-2-(p-tolylamino) butanamide



128.28, 113.75, 62.03, 50.62, 28.55, 26.65, 20.30, 10.27. HRMS (ESI-TOF) m/z $\rm [M+H]^+$ calcd for $\rm C_{15}H_{24}N_2O$ 249.1967; found 249.1965.

N-(tert-butyl)-2-((4-chlorophenyl) amino) butanamide



White solid, 204 mg, 79% yield, mp 123-124 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.14 (d, J = 8.8 Hz, 2H), 6.53 (d, J = 8.8 Hz, 2H), 6.43 (s, 1H), 3.95 (s, 1H), 3.47 – 3.43 (m, 1H), 2.00 – 1.89 (m, 1H), 1.81-1.75 (m, 1H), 1.30 (s, 9H), 1.02 (t, J = 7.5 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 171.96, 145.63, 129.20, 123.70, 114.87, 61.56, 50.96, 28.64, 26.51, 10.07. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₁₄H₂₁ClN₂O

269.1421; found 269.1425.

methyl (2-(pyridin-4-yl)-2-(p-tolylamino) acetyl) glycinate



129.40, 128.96, 124.92, 123.50, 121.77, 121.08, 52.12, 42.74, 21.08, 20.69. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{17}H_{19}N_3O_3$ 314.1505; found 314.1495.

methyl (2-(2-nitrophenyl)-2-(p-tolylamino) acetyl) glycinate



Yellow oil, 328 mg, 88% yield, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.99 (d, J = 8.1 Hz, 1H), 7.63 – 7.56 (m, 2H), 7.49 – 7.43 (m, 2H), 6.72 (d, J = 8.9 Hz, 2H), 6.52 (d, J = 8.9 Hz, 2H), 5.52 (s, 1H), 4.96 (s, 1H), 4.14 – 4.00 (m, 2H), 3.73 (s, 3H), 3.70 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 170.00, 169.76, 153.11, 148.89, 139.28,

134.26, 134.04, 130.44, 129.07, 125.09, 115.36, 114.90, 59.21, 55.59, 52.40, 41.37. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{18}H_{19}N_3O_6$ 374.1352; found 374.1353.

2-(4-fluorophenyl)-2-((4-methoxyphenyl) amino)-N-(tosylmethyl) acetamide



Yellow oil, 323 mg, 73% yield, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.55 (d, J = 7.2 Hz, 2H), 7.30 (d, J = 5.6 Hz, 2H), 7.17 (d, J = 7.6 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.78 (d, J = 7.6 Hz, 2H), 6.53 (d, J = 7.6 Hz, 2H), 4.86 – 4.76 (m, 1H), 4.63 (s, 1H), 4.57 – 4.49 (m, 1H), 4.13 (d, J = 7.2 Hz, 2H), 3.75 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100

MHz, CDCl₃) δ (ppm) 171.25, 163.99, 161.53, 153.66, 145.26, 139.85, 133.87, 129.79,

129.04, 128.96, 128.51, 115.93, 115.26, 114.97, 63.91, 59.95, 55.67, 21.63. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{23}H_{23}FN_2O_4S$ 443.1441; found 443.1445.

2-((4-chlorophenyl) amino)-2-(p-tolyl)-N-(tosylmethyl) acetamide



White solid, 314 mg, 71% yield, mp 198-199 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.52 (d, J = 8.1 Hz, 2H), 7.36 (t, J = 6.5 Hz, 1H), 7.22 – 7.15 (m, 6H), 7.09 (d, J = 8.6 Hz, 2H), 6.45 (d, J = 8.6 Hz, 2H), 4.73 – 4.57 (m, 4H), 2.38 (d, J = 12.9 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 170.92, 145.28, 144.63, 138.82, 134.36,

133.67, 129.98, 129.83, 129.19, 128.54, 127.05, 124.00, 114.94, 63.22, 60.05, 21.69, 21.15. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{23}H_{23}ClN_2O_3S$ 443.1196; found 443.1195.

2-(4-cyanophenyl)-N-cyclohexyl-2-(m-tolylamino) acetamide



Yellow solid, 319 mg, 92% yield, mp 146-147 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.66 (d, J = 7.9 Hz, 2H), 7.55 (d, J = 6.7 Hz, 2H), 7.08 (t, J = 7.5 Hz, 1H), 6.66-6.42 (m, 4H), 4.76 (s, 1H), 4.42 (s, 1H), 3.78 (s, 1H), 2.27 (s, 3H), 1.87-1.80 (m, 4H), 1.34 – 1.03 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 168.85,

146.05, 144.30, 139.41, 132.88, 129.26, 128.11, 120.60, 118.37, 114.66, 112.41, 110.99, 63.86, 48.44, 32.91, 25.41, 24.75, 21.51. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for C₂₂H₂₅N₃O 348.2076; found 348.2079.

2-((4-chlorophenyl) amino)-N-cyclohexyl-2-(2-methoxyphenyl) acetamide



White oil, 346 mg, 93% yield, mp 196-197 °C, ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.35 (d, J = 7.6 Hz, 1H), 7.26 (t, J = 7.8 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 7.00 – 6.91 (m, 2H), 6.57 (d, J = 7.7 Hz, 1H), 6.40 (d, J = 8.8 Hz, 2H), 5.20 (s, 1H), 3.97 (s, 3H), 1.92 (d, J = 8.8 Hz, 1H), 1.67 – 1.52 (m, 4H), 1.39 – 1.00 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 169.54, 156.24, 144.90, 129.06, 128.91, 127.38,

127.03, 122.10, 121.71, 114.31, 110.80, 55.57, 55.46, 47.91, 32.44, 25.43, 24.27. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{21}H_{25}ClN_2O_2$ 373.1683; found 373.1682.

N-benzyl-2-phenyl-2-(phenylamino) acetamide



White solid, 164 mg, 52% yield, mp 146-147 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.44 (d, J = 6.6 Hz, 1H), 7.41 – 7.32 (m, 2H), 7.29 – 7.22 (m, 2H), 7.18 (t, J = 7.8 Hz, 1H), 7.15 – 7.09 (m, 1H), 7.02 (s, 1H), 6.80 (t, J = 7.3 Hz, 1H), 6.63 (d, J = 7.9 Hz, 1H), 4.80 (d, J = 2.0 Hz, 1H), 4.54 (dd, J = 14.7, 6.4 Hz, 1H), 4.38 (dd, J = 14.9, 5.6 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 171.15, 146.52, 138.76, 137.90, 129.31, 129.24, 128.60, 127.51, 127.43, 127.34, 119.17, 113.86, 64.21, 43.41. HRMS

(ESI-TOF) m/z $[M+H]^+$ calcd for C₂₁H₂₁N₂O 317.1660; found 317.1654.

N-(4-methoxyphenyl)-2-phenyl-2-(phenylamino) acetamide



White solid, 146 mg, 44% yield, mp 150-151 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 8.61 (s, 1H), 7.49 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.43 – 7.35 (m, 3H), 7.22 (dd, *J* = 8.4, 7.5 Hz, 1H), 6.88 – 6.81 (m, 2H), 6.71 (d, *J* = 7.7 Hz, 1H), 4.82 (s, 1H), 4.48 (s, 1H), 3.77 (s, 2H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 169.23, 156.61, 146.53, 138.54,

130.38, 129.48, 129.33, 128.77, 127.42, 121.68, 119.75, 114.11, 65.27, 55.47. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{21}H_{21}N_2O_2$ 333.1608; found 333.1603.

N-(tert-butyl)-2-(methyl(phenyl) amino)-2-phenylacetamide



White solid, 193 mg, 65% yield, mp 165-166 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.34 – 7.27 (m, 3H), 7.23 (d, *J* = 7.2 Hz, 1H), 6.90 – 6.87 (m, 2H), 6.50 (s, 1H), 5.21 (s, 1H), 2.64 (s, 2H), 1.37 (s, 5H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 169.99, 150.26, 136.03, 129.25, 129.10, 128.42, 127.80, 119.22, 115.08, 70.41, 51.20, 35.64, 28.69. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₁₉H₂₅N₂O 297.1962; found 297.1967.

N-(tert-butyl)-2-(dibenzylamino)-2-phenylacetamide



White solid, 232 mg, 60% yield, mp 103-104 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.42 – 7.33 (m, 5H), 7.32 – 7.25 (m, 3H), 7.13 (s, 1H), 4.30 (s, 1H), 3.83 (d, *J* = 13.9 Hz, 1H), 3.34 (d, *J* = 13.9 Hz, 1H), 1.40 (s, 5H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 170.66, 138.77, 134.48, 130.33, 128.60, 128.54, 128.10, 127.68, 127.29, 68.10, 54.54, 50.97, 28.81. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₂₆H₃₁N₂O 387.2440; found 387.2436.

2-(2-azidophenyl)-N-(tert-butyl)-2-(phenylamino) acetamide



White solid, 259 mg, 80% yield, mp 137-138 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.42 (d, J = 8.8 Hz, 1H), 7.35 (t, J = 8.8 Hz, 1H), 7.21 (d, J = 6.8 Hz, 1H), 7.16 – 7.08 (m, 3H), 6.72 (t, J = 7.6 Hz, 1H), 6.52 (d, J = 8.8 Hz, 2H), 6.48 (s, 1H), 5.04 (d, J = 2.8 Hz, 1H,), 4.94 (s, 1H), 1.31 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 169.53, 146.11, 137.24, 130.66, 129.27, 129.20, 128.29, 125.68, 118.19, 113.42, 64.04, 57.04, 51.18,

28.58. HRMS (ESI-TOF) $m/z [M+H]^+$ calcd for $C_{18}H_{21}N_5O$ 324.1824; found 324.1824.

2-(2-azidophenyl)-N-(tert-butyl)-2-(p-tolylamino) acetamide



White solid, 300 mg, 89% yield, mp 152-153 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.40 (d, J = 7.6 Hz, 1H), 7.33 (t, J = 7.2 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 8.0 Hz, 2H), 6.57 (s, 1H), 6.46 (d, J = 8.4 Hz, 2H), 6.46 (d, J = 4.0 Hz, 1H), 4.68 (s, 1H), 2.21 (s, 3H), 1.32 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 169.64, 144.00, 137.39, 130.85, 129.71, 129.24, 128.46,

127.58, 125.60, 118.23, 113.60, 57.91, 51.43, 28.60, 20.43. HRMS (ESI-TOF) m/z $\rm [M+H]^+$ calcd for $\rm C_{19}H_{23}N_5O$ 338.1981; found 338.1978.

2-(2-azidophenyl)-N-(tert-butyl)-2-((4-methoxyphenyl) amino) acetamide



White solid, 300 mg, 85% yield, mp 136-137 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.40 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 8.4 Hz, 1H), 6.75 (d, J = 8.8 Hz, 2H), 6.62 (s, 1H), 6.52 (d, J = 8.8 Hz, 2H), 4.95 (s, 1H), 4.55 (s, 1H), 3.72 (s, 3H), 1.33 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 169.78, 152.66, 140.41, 137.48, 130.75, 129.26, 128.39, 125.55,

118.23, 114.65, 99.84, 58.66, 55.65, 51.22, 28.81. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for C₁₉H₂₃N₅O₂ 354.1930; found 354.1929.

2-(2-azidophenyl)-N-(tert-butyl)-2-((4-chlorophenyl) amino) acetamide



White solid, 296 mg, 83% yield, mp 163-164 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.39 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 8.4 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.11 (t, J = 7.6 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 6.41 (d, J = 8.8 Hz, 2H), 6.33 (s, 1H), 5.09 (s, 1H), 5.01 (s, 1H), 1.30 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 168.95, 144.54, 137.17, 130.27, 129.38, 129.03, 128.02, 125.7, 122.60, 118.16, 114.49,

56.82, 51.60, 28.58. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{18}H_{20}ClN_5O$ 358.1435; found 358.1439.

2-(2-azidophenyl)-N-(tert-butyl)-2-((4-fluorophenyl) amino) acetamide



White solid, 280 mg, 82% yield, mp 143-144 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.39 (d, *J* = 8.0 Hz, 1H), 7.34 (d, *J* = 7.6 Hz, 1H), 7.20 (d, *J* = 8.0 Hz, 1H), 7.11 (t, *J* = 8.0 Hz, 1H), 6.83 (d, *J* = 8.8 Hz, 2H), 6.47 – 6.39 (m, 3H), 6.27 (d, *J* = 4.8 Hz, 1H), 4.85 (s, 1H), 1.30 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 169.28, 157.35, 142.46, 137.22, 130.36, 129.35, 128.20, 125.68, 118.11, 115.78, 114.26, 57.64, 51.36,

28.58. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{18}H_{20}FN_5O$ 342.1730; found 342.1725.

2-(2-azidophenyl)-N-(tert-butyl)-2-((3-chlorophenyl) amino) acetamide



White solid, 282 mg, 79% yield, mp 144-145 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.42 – 7.32 (m, 2H), 7.22 (d, *J* = 8.8 Hz, 1H), 7.21 (t, *J* = 7.6 Hz, 1H), 7.04 – 6.97 (m, 1H), 6.64 (d, *J* = 7.6 Hz, 1H), 6.47 (d, *J* = 2.0 Hz, 1H), 6.35 (d, *J* = 7.6 Hz, 1H), 6.29 (s, 1H), 5.20 (s, 1H), 5.03 (s, 1H), 1.30 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 168.84, 147.09, 137.06, 134.81, 130.15, 129.42, 128.01, 125.73, 118.18,

117.87, 113.17, 111.50, 56.35, 51.43, 28.57. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{18}H_{20}ClN_5O$ 358.1435; found 358.1434.

2-(2-azidophenyl)-N-(tert-butyl)-2-(m-tolylamino) acetamide



Yellow solid, 273 mg, 81% yield, mp 150-151 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.41 (d, *J* = 7.7 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.21 (d, *J* = 7.3 Hz, 1H), 7.12 (t, *J* = 7.5 Hz, 1H), 7.02 (t, *J* = 7.8 Hz, 1H), 6.55 (d, *J* = 8.0 Hz, 2H), 6.40 (s, 1H), 6.32 (d, *J* = 8.0 Hz, 1H), 5.01 (d, *J* = 2.9 Hz, 1H), 4.77 (s, 1H), 2.24 (s, 3H), 1.32 (s, 9H);¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 169.62, 146.27, 139.02, 137.35, 130.77, 129.27, 129.08, 128.38, 125.64, 119.33, 118.24, 114.43,

110.49, 57.67, 51.27, 28.59, 21.55. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{19}H_{24}N_5O$ 338.1985; found 338.1981.

2-(2-azidophenyl)-N-(tert-butyl)-2-((2-chlorophenyl) amino) acetamide



Yellow solid, 275 mg, 77% yield, mp 109-110 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.41 (d, J = 7.7 Hz, 1H), 7.36 – 7.33 (m, 1H), 7.26 – 7.22 (m, 2H), 7.12 (t, J = 7.5 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 6.62 (t, J = 7.2 Hz, 1H), 6.42 – 6.23 (m, 2H), 5.76 (d, J = 4.2 Hz, 1H), 5.09 (d, J = 4.7 Hz, 1H), 1.31 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 168.80, 142.00, 137.20, 130.15, 129.40, 129.20, 128.04, 127.65, 125.83, 119.82, 118.15, 118.07,

112.14, 56.46, 51.47, 28.61. HRMS (ESI-TOF) $m/z [M+H]^+$ calcd for $C_{18}H_{21}N_5OCl$ 358.1437; found 358.1435.

methyl (2-(2-azidophenyl)-2-(phenylamino) acetyl) glycinate



Yellow solid, 231 mg, 68% yield, mp 125-126 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.48 (d, J = 8.0 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.22 (d, J = 8.4 Hz, 2H), 7.17 – 7.09 (m 3H), 6.73 (t, J = 7.2 Hz, 1H), 6.54 (d, J = 7.6 Hz, 2H), 5.25 (d, J = 4.0 Hz, 1H), 4.95 (s, 1H), 4.19 – 4.10 (m, 1H), 4.01 – 3.92 (m, 1H), 3.73 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 170.75, 169.89, 145.93, 137.53, 129.82, 129.53, 129.25,

128.38, 125.65, 118.40, 118.23, 113.47, 56.67, 52.39, 41.37. HRMS (ESI-TOF) m/z $\rm [M+H]^+$ calcd for $\rm C_{17}H_{17}N_5O_3$ 340.1410; found 340.1408.

methyl (2-(2-azidophenyl)-2-((3-bromophenyl) amino) acetyl) glycinate



Yellow solid, 254 mg, 61% yield, mp 140-141 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.43 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 7.15 – 7.06 (m, 2H), 6.96 (t, J = 8.0 Hz, 1H), 6.81 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 6.41 (d, J = 8.0 Hz, 1H), 5.24 (d, J = 5.2 Hz, 1H), 5.17 (d, J = 4.8 Hz, 1H), 4.16 – 4.07 (m, 2H), 3.74 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 170.14,

169.79, 147.07, 137.48, 130.52, 129.72, 129.26, 128.14, 125.76, 123.16, 121.10, 118.27, 116.29, 111.93, 56.05, 52.31, 41.42. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{17}H_{16}BrN_5O_3$ 418.0515; found 418.0515.

methyl (2-(2-azidophenyl)-2-(p-tolylamino) acetyl) glycinate



Yellow solid, 290 mg, 82% yield, mp 157-158 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.46 (d, J = 8.0 Hz, 1H), 7.37 -7.28 (m, 2H), 7.21 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 5.20 (s, 1H), 4.73 (s, 1H), 4.20 - 4.12 (m, 1H), 4.00 - 3.92 (m, 1H), 3.73 (s, 3H), 2.21 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 171.02, 169.91, 143.70, 137.60, 129.88, 129.75,

129.51, 128.45, 127.77, 125.59, 118.24, 113.59, 57.23, 52.35, 41.30, 20.36. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{18}H_{19}N_5O_3$ 354.1566; found 354.1568.

methyl (2-(2-azidophenyl)-2-((4-methoxyphenyl) amino) acetyl) glycinate



Yellow solid, 295 mg, 80% yield, mp 142-143 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.46 (d, *J* = 7.6 Hz, 1H), 7.35 (d, *J* = 8.0 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 1H), 7.12 (t, *J* = 7.2 Hz, 1H), 6.74 (d, *J* = 8.8 Hz, 2H), 6.53 (d, *J* = 8.8 Hz, 2H), 5.15 (s, 1H), 4.57 (s, 1H), 4.20 – 4.11 (m, 1H), 4.01 – 3.93 (m, 1H), 3.73 (s, 3H), 3.71 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 171.11, 169.94, 152.79,

140.21, 137.64, 129.95, 129.51, 128.53, 127.08, 125.55, 118.25, 114.82, 57.94, 55.64, 52.35, 41.28. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{18}H_{19}N_5O_4$ 370.1515; found 370.1511.

methyl (2-(2-azidophenyl)-2-((4-chlorophenyl) amino) acetyl) glycinate



128.11, 125.71, 122.91, 118.24, 114.50, 56.24, 52.45, 41.42. HRMS (ESI-TOF) m/z $\rm [M+H]^+$ calcd for $\rm C_{17}H_{16}ClN_5O_3$ 374.1020; found 374.1019.

2-(2-azidophenyl)-2-(phenylamino)-N-(tosylmethyl) acetamide



Yellow solid, 264 mg, 67% yield, mp 168-169 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.43 (d, J = 8.4 Hz, 4H), 7.28 (s, 1H), 7.12 (t, J = 8.0 Hz, 5H), 6.73 (t, J= 7.6 Hz, 1H), 6.44 (d, J = 8.0 Hz, 2H), 5.16 (d, J = 4.4 Hz, 1H), 4.85 – 4.75 (m, 2H), 4.59 – 4.52 (m, 1H), 4.12 (d, J = 6.4 Hz, 1H), 2.38 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 170.11, 145.47, 145.16,

137.54, 133.79, 129.84, 129.76, 129.30, 129.05, 128.42, 128.30, 125.64, 118.59, 118.25, 113.41, 60.07, 56.38, 21.67. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{22}H_{22}N_2O_3S$ 395.1429; found 395.1428.

2-(2-azidophenyl)-2-((4-methoxyphenyl) amino)-N-(tosylmethyl) acetamide



Yellow solid, 326 mg, 70% yield, mp 133-134 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.56 (t, J = 6.7 Hz, 1H), 7.47 (d, J = 8.3 Hz, 2H), 7.40 (td, J = 8.0, 1.5 Hz, 1H), 7.32 – 7.19 (m, 3H), 7.19 – 7.07 (m, 3H), 6.77 – 6.66 (m, 2H), 6.49 – 6.38 (m, 2H), 5.07 (s, 1H), 4.78 (dd, J = 14.2, 7.5 Hz, 1H), 4.59 (dd, J = 14.2, 6.1 Hz, 1H), 3.71 (s, 3H), 2.39 (s, 3H); ¹³C NMR

2-(2-azidophenyl)-N-cyclohexyl-2-(p-tolylamino) acetamide



White solid, 282 mg, 80% yield, mp 152-153 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.40 (d, J = 7.6Hz, 1H), 7.33 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.10 (t, J = 7.2 Hz, 1H), 6.95 (d, J = 8.4 Hz, 2H), 6.60 (d, J = 8.0 Hz, 1H), 6.47 (d, J = 8.4 Hz, 2H), 5.05 (s, 1H), 3.77 (t, J = 4.0 Hz, 1H), 2.21 (s, 3H), 1.93 (d, J = 8.8 Hz, 2H), 1.79 – 1.65 (m, 2H), 1.63 – 1.53 (m, 2H), 1.48 – 0.95 (m, 6H); ¹³C

NMR (CDCl₃, 100 MHz) δ (ppm) 169.52, 144.01, 137.49, 130.56, 129.71, 129.32, 128.42, 127.62, 125.58, 118.22, 113.58, 57.66, 48.13, 32.96, 25.41, 24.61, 20.35. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₂₂H₂₈N₂O₂ 353.2229; found 353.2230.

2-(2-azidophenyl)-N-cyclohexyl-2-((4-methoxyphenyl) amino) acetamide



White solid, 320 mg, 87% yield, mp 157-158 °C, ¹H NMR (CDCl₃, 400 MHz,) δ (ppm) 7.39 (d, J = 7.6 Hz, 1H), 7.33 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.11 (t, J = 7.6 Hz, 1H), 6.74 (d, J = 8.8 Hz, 2H), 6.64 (d, J = 8.0 Hz, 1H), 6.52 (d, J = 8.8 Hz, 2H), 5.01 (s, 1H), 3.90 – 3.50 (m, 5H), 1.94 (d, J = 8.8 Hz, 1H), 1.80 – 1.55 (m, 4H), 1.40 – 1.06 (m, 5H); ¹³C NMR (CDCl₃, 100 MHz)

δ (ppm) 169.60, 152.70, 140.38, 137.60, 130.55, 129.34, 128.46, 125.54, 118.24, 114.79, 99.96, 58.31, 55.64, 48.10, 32.61, 25.41, 24.51. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₂₂H₂₈N₂O₃ 369.2178; found 369.2179.

2-(2-azidophenyl)-2-((4-chlorophenyl) amino)-N-cyclohexylacetamide



White solid, 299 mg, 78% yield, mp 178-179 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.39 (dd, J = 7.8, 1.4 Hz, 1H), 7.35 (td, J = 7.9, 1.5 Hz, 1H), 7.24 – 7.18 (m, 1H), 7.11 (td, J = 7.7, 0.9 Hz, 1H), 7.08 – 7.01 (m, 2H), 6.45 – 6.39 (m, 2H), 6.36 (d, J = 8.1 Hz, 1H), 5.07 (s, 2H), 3.80 – 3.69 (m, 1H), 1.94 (dd, J = 12.1, 3.4 Hz, 1H), 1.70 (dd, J = 8.0, 4.8 Hz, 2H), 1.58 (d, J = 12.5 Hz, 2H), 1.43 – 1.27 (m, 2H), 1.25

-1.11 (m, 2H), 1.04 (td, *J* = 13.8, 3.3 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 168.88, 144.53, 137.28, 130.01, 129.48, 129.06, 128.10, 125.77, 122.72, 118.18, 114.44, 56.50, 48.30, 32.90, 32.54, 25.39, 24.55, 24.44. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₂₀H₂₃N₅OCl 384.1596; found 384.1591.

2-(2-azidophenyl)-N-butyl-2-(p-tolylamino) acetamide



Yellow solid, 246 mg, 73% yield, mp 129-130 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.44 – 7.38 (m, 1H), 7.36 – 7.31 (m, 1H), 7.20 (d, *J* = 7.3 Hz, 1H), 7.11 (t, *J* = 7.5 Hz, 1H), 6.95 (d, *J* = 8.2 Hz, 2H), 6.64 (s, 1H), 6.46 (d, *J* = 8.4 Hz, 2H), 5.09 (s, 1H), 4.74 (s, 1H), 3.36 – 3.17 (m, 2H), 2.21 (s, 3H), 1.50 – 1.41 (m, 2H), 1.27 (dq, *J* = 14.5, 7.3 Hz, 2H), 0.88 (t, *J* = 7.3 Hz, 3H).; ¹³C NMR (CDCl₃, 100 MHz) δ

(ppm) 170.47, 143.87, 137.43, 130.50, 129.74, 129.35, 128.46, 127.60, 125.63, 118.21, 113.54, 57.41, 39.34, 31.52, 20.36, 19.92, 13.65. HRMS (ESI-TOF) m/z $[M+H]^+$ calcd for $C_{19}H_{24}N_5$ 338.1988; found 338.1981.

2-(2-azidophenyl)-2-((3-bromophenyl) amino)-N-butylacetamide



Yellow solid, 301 mg, 75% yield, mp 113-114 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.44 – 7.31 (m, 2H), 7.23 (d, J = 7.3 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 6.95 (t, J = 8.0 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 6.66 (t, J = 2.0 Hz, 1H), 6.41 – 6.38 (m, 2H), 5.23 (d, J = 4.8 Hz, 1H), 5.12 (d, J = 4.9 Hz, 1H), 3.34 – 3.16 (m, 2H), 1.50 – 1.39 (m, 2H), 1.26 (dq, J = 20, 8.0 Hz, 2H), 0.88 (t, J = 7.3 Hz, 3H); ¹³C NMR (CDCl₃, 100

MHz) δ (ppm) 169.68, 147.20, 137.20, 130.48, 129.85, 129.55, 128.13, 125.82, 123.12, 120.85, 118.17, 116.14, 111.83, 55.91, 39.46, 31.45, 19.87, 13.62. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₁₈H₂₁N₅OBr 402.0936; found 402.0929.

2-(2-azidophenyl)-2-(benzylamino)-N-(tert-butyl) acetamide



White solid, 162 mg, 48% yield, mp 77-78 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.36 – 7.29 (m, 6H), 7.26 – 7.24 (m, 1H), 7.17 (dd, J = 7.9, 0.7 Hz, 1H), 7.11 (td, J = 7.5, 1.0 Hz, 1H), 4.28 (s, 1H), 3.74 (dd, J = 39.0, 12.9 Hz, 2H), 2.63 – 1.54 (m, 2H), 1.37 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 170.76, 139.38, 137.81, 131.10, 129.71, 129.05, 128.49, 128.24, 127.29, 125.01, 118.53, 62.64, 52.58, 50.74, 28.70. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for C₁₉H₂₄N₅O 338.1987; found

338.1981.

2-(2-azidophenyl)-N-(tert-butyl)-2-((thiophen-2-ylmethyl) amino) acetamide



White solid, 189 mg, 55% yield, mp 111-112 °C, ¹H NMR (CDCl₃, 400 MHz) δ (ppm) 7.40 – 7.30 (m, 2H), 7.26 – 7.23 (m, 2H), 7.19 – 7.08 (m, 2H), 6.95 (dd, *J* = 5.0, 3.5 Hz, 1H), 6.91 (d, *J* = 2.7 Hz, 1H), 4.29 (s, 1H), 4.02 (d, *J* = 13.9 Hz, 1H), 3.85 (d, *J* = 13.9 Hz, 1H), 2.29 (s, 1H), 1.38 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz) δ (ppm) 170.53, 143.23, 137.82, 130.76, 129.96, 129.12, 126.68, 125.24, 124.98, 124.77, 118.57, 62.40, 50.77, 47.03, 28.68. HRMS (ESI-TOF) m/z [M+H]⁺ calcd for

 $C_{17}H_{22}N_5OS$ 344.1554; found 344.1545.

4. Copies of ¹H and ¹³C NMR spectra of compounds 4 and 5



¹H NMR (400 MHz, CDCl₃) spectra of product 4a.

¹H NMR (400 MHz, CDCl₃) spectra of product 4b.



¹H NMR (400 MHz, CDCl₃) spectra of product 4c.





S21

¹H NMR (400 MHz, CDCl₃) spectra of product 4d.



¹H NMR (400 MHz, CDCl₃) spectra of product 4e.



¹H NMR (400 MHz, CDCl₃) spectra of product 4f.



¹H NMR (400 MHz, CDCl₃) spectra of product 4g.





¹³C NMR (100 MHz, CDCl₃) spectra of product 4g.

	-159.73	-147.92	130.80 130.46 130.46 123.09 123.09 123.09 112.34 112.34	77.32 77.00 76.68	-63.30	55.41 51.33	
--	---------	---------	--	-------------------------	--------	----------------	--



¹H NMR (400 MHz, CDCl₃) spectra of product 4h.



S26







¹H NMR (400 MHz, CDCl₃) spectra of product 4j.





¹H NMR (400 MHz, CDCl₃) spectra of product 4k.



¹H NMR (400 MHz, CDCl₃) spectra of product 4l.



---0.00





¹³C NMR (100 MHz, CDCl₃) spectra of product 4l.

-171.25	~164.00 ~161.53	-153.66	7145.26 7139.85 7129.79 7129.04 7129.04 7128.96 7128.51	√115.93 -115.26 ∿114.97	-77.32 -77.00 -76.68 -66.68 -63.91 -59.95 -55.67	-21.63
) (I





¹H NMR (400 MHz, CDCl₃) spectra of product 4m.





¹³C NMR (100 MHz, CDCl₃) spectra of product 4m.

-170.92 145.28 145.28 133.636 133.636 133.636 123.938 29.938 129.93 129.93 129.19 127.05 -114.94	$\begin{array}{c} & \begin{array}{c} & & & \\ & & & & \\ & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ $	21.69
--	--	-------



---0.00

¹H NMR (400 MHz, CDCl₃) spectra of product 4n.



---0.00



¹³C NMR (100 MHz, CDCl₃) spectra of product 4n.



¹H NMR (400 MHz, CDCl₃) spectra of product 40.



¹H NMR (400 MHz, CDCl₃) spectra of product 4p.





¹³C NMR (100 MHz, CDCl₃) spectra of product 4p.



¹H NMR (400 MHz, CDCl₃) spectra of product 4q.



-1

¹H NMR (400 MHz, CDCl₃) spectra of product 4t.

-1

¹H NMR (400 MHz, CDCl₃) spectra of product 4u.

¹H NMR (400 MHz, CDCl₃) spectra of product 5a.

¹H NMR (400 MHz, CDCl₃) spectra of product 5b.

¹H NMR (400 MHz, CDCl₃) spectra of product 5c.

¹H NMR (400 MHz, CDCl₃) spectra of product 5d.

S41

¹H NMR (400 MHz, CDCl₃) spectra of product 5e.

S43

¹H NMR (400 MHz, CDCl₃) spectra of product 5h.

¹H NMR (400 MHz, CDCl₃) spectra of product 5i.

¹H NMR (400 MHz, CDCl₃) spectra of product 5j.

¹H NMR (400 MHz, CDCl₃) spectra of product 5k.

 $\begin{array}{c} & -2.21 \\ \hline & -2.21 \\ \hline$

¹H NMR (400 MHz, CDCl₃) spectra of product 5l.

S49

¹H NMR (400 MHz, CDCl₃) spectra of product 5m.

¹H NMR (400 MHz, CDCl₃) spectra of product 5n.

¹H NMR (400 MHz, CDCl₃) spectra of product 50.

¹³C NMR (100 MHz, CDCl₃) spectra of product 50.

	$\begin{array}{c} 139.66 \\ 129.75 \\ 129.71 \\ 129.17 \\ 129.17 \\ 128.41 \\ 128.41 \\ 114.86 \\ 114.86 \\ 114.76 \end{array}$	$\underbrace{\int_{76.68}^{77.32}}$	~60.05 ~57.58 ~55.66	-21.69
--	---	-------------------------------------	----------------------------	--------

¹H NMR (400 MHz, CDCl₃) spectra of product 5p.

¹H NMR (400 MHz, CDCl₃) spectra of product 5q.

¹H NMR (400 MHz, CDCl₃) spectra of product 5r.

S55

¹H NMR (400 MHz, CDCl₃) spectra of product 5s.

¹H NMR (400 MHz, CDCl₃) spectra of product 5t.

 $\begin{array}{l} \mathcal{A}_{2} \mathcal{A}$

S57

¹H NMR (400 MHz, CDCl₃) spectra of product 5v.

